Inhibition of cytokine-induced sh2 protein in nk cells
AssigneeThe Walter and Eliza Hall Institute of Medical Research
InventorsNicholas D. Huntington, Sandra E. Nicholson
Life of this patent
Estimating the term…
Abstract
The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition
Claims14
1-64. (canceled)
CIS-inhibited human NK cells, wherein the CIS-inhibited human NK cells are genetically modified to have reduced expression of CIS, or are genetically modified to express a dominant negative CIS sequence variant or dominant negative fragment thereof.
Human Cish−/+ NK cells.
Human Cish−/− NK cells.
Dependencies are inferred from the claim text.